BACKGROUND: Schizophrenia and alcohol dependence are major risk factors for a variety of medical problems, yet there has been little research on the medical status of patients in whom both conditions coexist. METHODS: We assessed the prevalence and severity of medical illness in 80 patients with schizophrenia or schizoaffective disorder and comorbid alcohol use disorders who entered a controlled trial of monitored naltrexone treatment, and analyzed the relationship between medical illness burden and demographic variables, alcohol and other substance use, and psychosis. Participants underwent physical examination, laboratory tests, medical record review and standardized assessments of medical illness burden, alcohol and other substance use, and psychosis. Nested block multiple regression analyses were used to assess the contribution to illness burden made by demographic variables, alcohol and substance use, and psychosis severity. RESULTS: 83% of participants had at least one chronic medical illness, hypertension being the most common (43%). Medical comorbidity in this cohort was more severe than for schizophrenia patients in the CATIE trial (Chwastiak, L., Rosenheck, R., McEvoy, J.P., Keefe, R.S., Swartz, M.S., Lieberman, J.A., 2006. Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatr. Serv., 57(8), 1102-1109.); the prevalence of hypertension, chronic obstructive pulmonary disease, and coronary artery disease, was more than twice greater. Medical illness burden correlated with alcohol use severity, but appeared to be independent of other substance use or psychosis severity. CONCLUSIONS: Patients with co-occurring alcohol use disorder may have significantly more medical illness burden than patients with schizophrenia or schizoaffective disorder alone. Interventions to reduce alcohol use may be necessary to lessen medical morbidity.
BACKGROUND:Schizophrenia and alcohol dependence are major risk factors for a variety of medical problems, yet there has been little research on the medical status of patients in whom both conditions coexist. METHODS: We assessed the prevalence and severity of medical illness in 80 patients with schizophrenia or schizoaffective disorder and comorbid alcohol use disorders who entered a controlled trial of monitored naltrexone treatment, and analyzed the relationship between medical illness burden and demographic variables, alcohol and other substance use, and psychosis. Participants underwent physical examination, laboratory tests, medical record review and standardized assessments of medical illness burden, alcohol and other substance use, and psychosis. Nested block multiple regression analyses were used to assess the contribution to illness burden made by demographic variables, alcohol and substance use, and psychosis severity. RESULTS: 83% of participants had at least one chronic medical illness, hypertension being the most common (43%). Medical comorbidity in this cohort was more severe than for schizophreniapatients in the CATIE trial (Chwastiak, L., Rosenheck, R., McEvoy, J.P., Keefe, R.S., Swartz, M.S., Lieberman, J.A., 2006. Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatr. Serv., 57(8), 1102-1109.); the prevalence of hypertension, chronic obstructive pulmonary disease, and coronary artery disease, was more than twice greater. Medical illness burden correlated with alcohol use severity, but appeared to be independent of other substance use or psychosis severity. CONCLUSIONS:Patients with co-occurring alcohol use disorder may have significantly more medical illness burden than patients with schizophrenia or schizoaffective disorder alone. Interventions to reduce alcohol use may be necessary to lessen medical morbidity.
Authors: Lydia A Chwastiak; Robert A Rosenheck; Joseph P McEvoy; Richard S Keefe; Marvin S Swartz; Jeffrey A Lieberman Journal: Psychiatr Serv Date: 2006-08 Impact factor: 3.084
Authors: Claudio Castillo; Antoni Bulbena; Enric Serras; Marta Torrens; José Luís López-Colomés; María-Alba Martínez; Barbara Politinska Journal: Eur Addict Res Date: 2004 Impact factor: 3.015
Authors: Joseph Sokal; Erick Messias; Faith B Dickerson; Julie Kreyenbuhl; Clayton H Brown; Richard W Goldberg; Lisa B Dixon Journal: J Nerv Ment Dis Date: 2004-06 Impact factor: 2.254
Authors: Zsuzsa Szombathyne Meszaros; Jacqueline A Dimmock; Robert J Ploutz-Snyder; Ynesse Abdul-Malak; Luba Leontieva; Kelly Canfield; Steven L Batki Journal: Am J Addict Date: 2011-07-18
Authors: Nicholas J Chesher; Chad A Bousman; Maiken Gale; Sonya B Norman; Elizabeth W Twamley; Robert K Heaton; Ian P Everall; Patricia A Judd Journal: Am J Addict Date: 2011-12-15
Authors: Stanley N Caroff; Shirley H Leong; Daisy Ng-Mak; E Cabrina Campbell; Rosalind M Berkowitz; Krithika Rajagopalan; Chien-Chia Chuang; Antony Loebel Journal: Community Ment Health J Date: 2017-12-28
Authors: Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht Journal: World Psychiatry Date: 2011-02 Impact factor: 49.548
Authors: Zsuzsa Szombathyne Meszaros; Jacqueline A Dimmock; Robert Ploutz-Snyder; Sumerendra Vir Singh Chauhan; Ynesse Abdul-Malak; Frank A Middleton; Steven L Batki Journal: Schizophr Res Date: 2011-08-17 Impact factor: 4.939
Authors: Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giovanni Dominici; Stefano Ferracuti; Giorgio D Kotzalidis; Giulia Serra; Paolo Girardi; Luigi Janiri; Roberto Tatarelli; Leo Sher; David Lester Journal: Int J Environ Res Public Health Date: 2010-03-29 Impact factor: 3.390